Drug development: describes the process of developing a new drug that energetically targets a specific weakness in a cell. The process consist of bringing a new pharmaceutical drug to the market once a lead compound has been identified through the process of drug discovery.
Human breast tumors have been shown to exhibit extensive inter- and intra-tumor heterogeneity. While recent advances in genomic technologies have allowed us to deconvolute this heterogeneity,...
Emerging technologies facilitate basic science research, but their value in regulatory applications requires rigorous assessment and consensus within the research community. Next-generation s...
Complex recombinant protein biologics, such as monoclonal antibodies and coagulation factors, are key components of today’s biopharmaceutical industry. There are many effective paths fo...
CHO cells are the predominant host for biotherapeutic protein expression, with roughly 70% of licensed biologics manufactured in CHO. Multiple attributes make CHO cells desirable for bi...
Reliability from gene sequence to the expressed and purified protein is essential for many aspects of basic research and drug development. Thermo Fisher Scientific’s complete portfolio ...
A recently discovered communication system used by cells to send messages across the human body promises to revolutionize our understanding of disease and how we treat it. Technologies based...
Cervical cancer screening has been the 20th century poster child for preventative screening. This presentation is a gynecologist’s perspective on its continuing evolution –b...
The Personalized Medicine Initiative (PMI) is a non-profit enterprise based in Vancouver, Canada that is focused on introducing personalized, molecularly-based medicine into the front lines o...
In this webinar the speaker discusses the approach taken by the Food and Drug administration in their pre-market review of in vitro diagnostic tests. The legal bar passed by congress in...
We have been developing methods to target drugs specifically to pathologic cells, thereby avoiding collateral toxicity to healthy cells. In the case of cancer, we have exploited up-regulation...
Cancer remains the second leading cause of death in the United States. Most tumors arise from a myriad of genetic changes that dysregulate cell growth and prompt survival. Ident...
Success of the personalized medicine strategy depends on our ability to access the genetic variance landscape continuously before, during and after treatment. Liquid biopsies provide us...
Schizophrenia, depression, bipolar disorder are all uniquely human conditions. Psychiatric conditions include alterations in several different and overlapping domains (NIMH RDoC). Each...
Drug addiction is a chronically relapsing disorder characterized by compulsive drug use despite catastrophic personal consequences (e.g., loss of family, job) and even when the substance is n...
There is a growing appreciation of the relationship between gut microbiota, and the host in maintaining homeostasis in health and predisposing to disease. Bacterial colonisation of the gut pl...
The greatest health epidemic of our time is cancer. Deaths from cancer worldwide outnumber the combined deaths from HIV/AIDS, tuberculosis and malaria by a wide margin. There are at least 100...
While next-generation sequencing has proven to be a very useful tool in basic research, two major hurdles remain for its broad adoption in the clinical research setting: lack of seamless work...
The advent of the microarray technology in 2000 has paved the way for advanced translational research methods that use molecular markers such as microRNA, proteins, metabolites and copy numbe...
Cell death is involved in diseases such as cancer and neurodegeneration, and also has a natural role in the development of multicellular organisms. Although apoptosis has been well defined, a...
Every day, vast amounts of healthcare data are collected from clinical trials as well as real world medical visits on patient treatment regimens and subsequent clinical outcomes. This big dat...
On January 20, 2015, President Obama announced the Precision Medicine Initiative® (PMI) (link is external) in his State of the Union address. Through advances in research, technology and...
One of the primary goals of precision medicine is the aggregation and interpretation of deep, longitudinal patient-specific data in the context of the digital universe of information, using a...
A number of recently publications have heralded the advent of Precision Medicine in Oncology, where next generation sequencing technology, other ’omics technologies, serial biopsies, so...
In December 2012 the UK Prime Minister announced the 100,000 genomes project to introduce whole genome sequencing for treatment into the UK National Health Service (NHS) o...
Human breast tumors have been shown to exhibit extensive inter- and intra-tumor heterogeneity. While recent advances in genomic technologies have allowed us to deconvolute this heterogeneity,...
Emerging technologies facilitate basic science research, but their value in regulatory applications requires rigorous assessment and consensus within the research community. Next-generation s...
Complex recombinant protein biologics, such as monoclonal antibodies and coagulation factors, are key components of today’s biopharmaceutical industry. There are many effective paths fo...
CHO cells are the predominant host for biotherapeutic protein expression, with roughly 70% of licensed biologics manufactured in CHO. Multiple attributes make CHO cells desirable for bi...
Reliability from gene sequence to the expressed and purified protein is essential for many aspects of basic research and drug development. Thermo Fisher Scientific’s complete portfolio ...
A recently discovered communication system used by cells to send messages across the human body promises to revolutionize our understanding of disease and how we treat it. Technologies based...
Cervical cancer screening has been the 20th century poster child for preventative screening. This presentation is a gynecologist’s perspective on its continuing evolution –b...
The Personalized Medicine Initiative (PMI) is a non-profit enterprise based in Vancouver, Canada that is focused on introducing personalized, molecularly-based medicine into the front lines o...
In this webinar the speaker discusses the approach taken by the Food and Drug administration in their pre-market review of in vitro diagnostic tests. The legal bar passed by congress in...
We have been developing methods to target drugs specifically to pathologic cells, thereby avoiding collateral toxicity to healthy cells. In the case of cancer, we have exploited up-regulation...
Cancer remains the second leading cause of death in the United States. Most tumors arise from a myriad of genetic changes that dysregulate cell growth and prompt survival. Ident...
Success of the personalized medicine strategy depends on our ability to access the genetic variance landscape continuously before, during and after treatment. Liquid biopsies provide us...
Schizophrenia, depression, bipolar disorder are all uniquely human conditions. Psychiatric conditions include alterations in several different and overlapping domains (NIMH RDoC). Each...
Drug addiction is a chronically relapsing disorder characterized by compulsive drug use despite catastrophic personal consequences (e.g., loss of family, job) and even when the substance is n...
There is a growing appreciation of the relationship between gut microbiota, and the host in maintaining homeostasis in health and predisposing to disease. Bacterial colonisation of the gut pl...
The greatest health epidemic of our time is cancer. Deaths from cancer worldwide outnumber the combined deaths from HIV/AIDS, tuberculosis and malaria by a wide margin. There are at least 100...
While next-generation sequencing has proven to be a very useful tool in basic research, two major hurdles remain for its broad adoption in the clinical research setting: lack of seamless work...
The advent of the microarray technology in 2000 has paved the way for advanced translational research methods that use molecular markers such as microRNA, proteins, metabolites and copy numbe...
Cell death is involved in diseases such as cancer and neurodegeneration, and also has a natural role in the development of multicellular organisms. Although apoptosis has been well defined, a...
Every day, vast amounts of healthcare data are collected from clinical trials as well as real world medical visits on patient treatment regimens and subsequent clinical outcomes. This big dat...
On January 20, 2015, President Obama announced the Precision Medicine Initiative® (PMI) (link is external) in his State of the Union address. Through advances in research, technology and...
One of the primary goals of precision medicine is the aggregation and interpretation of deep, longitudinal patient-specific data in the context of the digital universe of information, using a...
A number of recently publications have heralded the advent of Precision Medicine in Oncology, where next generation sequencing technology, other ’omics technologies, serial biopsies, so...
In December 2012 the UK Prime Minister announced the 100,000 genomes project to introduce whole genome sequencing for treatment into the UK National Health Service (NHS) o...
Follow
